Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00612170 | A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia. | PHASE3 | COMPLETED | 1,129 | — | — | Dec 1, 2007 | May 1, 2009 | Dec 12, 2019 | 145 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| 3 | EXPERIMENTAL | - |
| 4 | SHAM_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| [S,S]-Reboxetine | DRUG | 10 mg oral tablet once a day dosing |
| Placebo | DRUG | 0 mg oral tablet once a day dosing |
Inclusion Criteria: * Male or female of any race, at least 18 years of age * Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites) Exclusion Criteria: * Patients with other severe pain (e...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Axsome Therapeutics, Inc. | AXSM | 1 | PHASE3 | AXS-14 |
| Grace Therapeutics, Inc. | GRCE | 1 | — | Undisclosed |